148 related articles for article (PubMed ID: 32745462)
21. [Clinical Significance of Detecting Tissue Factor and Tissue Factor Pathway Inhibitor in Thalassemia Patients].
Liu H; Sun N; Huang YL; Su X; Deng DH; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1471-1476. PubMed ID: 30295270
[TBL] [Abstract][Full Text] [Related]
22. Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model.
Crispel Y; Axelman E; Tatour M; Kogan I; Nevo N; Brenner B; Nadir Y
Thromb Haemost; 2016 Sep; 116(4):669-78. PubMed ID: 27535490
[TBL] [Abstract][Full Text] [Related]
23. Heparanase level and procoagulant activity are reduced in severe sepsis.
Matan M; King D; Peled E; Ackerman S; Bar-Lavi Y; Brenner B; Nadir Y
Eur J Haematol; 2018 Feb; 100(2):182-188. PubMed ID: 29120525
[TBL] [Abstract][Full Text] [Related]
24. Heparanase multiple effects in cancer.
Nadir Y; Brenner B
Thromb Res; 2014 May; 133 Suppl 2():S90-4. PubMed ID: 24862152
[TBL] [Abstract][Full Text] [Related]
25. Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.
Abu El-Asrar AM; Siddiquei MM; Nawaz MI; De Hertogh G; Mohammad G; Alam K; Mousa A; Opdenakker G
Mol Vis; 2016; 22():424-35. PubMed ID: 27168718
[TBL] [Abstract][Full Text] [Related]
26. Tissue factor-heparanase complex: intracellular nonhemostatic effects.
Ghanem S; Keren-Politansky A; Kaplan V; Crispel Y; Nadir Y
Res Pract Thromb Haemost; 2023 Aug; 7(6):102179. PubMed ID: 37767062
[TBL] [Abstract][Full Text] [Related]
27. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
28. Microparticles from splenectomized β-thalassemia/HbE patients play roles on procoagulant activities with thrombotic potential.
Klaihmon P; Phongpao K; Kheansaard W; Noulsri E; Khuhapinant A; Fucharoen S; Morales NP; Svasti S; Pattanapanyasat K; Chaichompoo P
Ann Hematol; 2017 Feb; 96(2):189-198. PubMed ID: 27900452
[TBL] [Abstract][Full Text] [Related]
29. Heparanase Level in the Microcirculation as a Possible Modulator of the Metastatic Process.
Nevo N; Ghanem S; Crispel Y; Tatour M; Cohen H; Kogan I; Ben-Arush M; Nadir Y
Am J Pathol; 2019 Aug; 189(8):1654-1663. PubMed ID: 31128083
[TBL] [Abstract][Full Text] [Related]
30. Heparanase role in the treatment of avascular necrosis of femur head.
Peled E; Davis M; Axelman E; Norman D; Nadir Y
Thromb Res; 2013 Jan; 131(1):94-8. PubMed ID: 23063054
[TBL] [Abstract][Full Text] [Related]
31. Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes.
Witkowski M; Witkowski M; Saffarzadeh M; Friebel J; Tabaraie T; Ta Bao L; Chakraborty A; Dörner A; Stratmann B; Tschoepe D; Winter SJ; Krueger A; Ruf W; Landmesser U; Rauch U
Cardiovasc Diabetol; 2020 Feb; 19(1):20. PubMed ID: 32066445
[TBL] [Abstract][Full Text] [Related]
32. Heparanase induces tissue factor expression in vascular endothelial and cancer cells.
Nadir Y; Brenner B; Zetser A; Ilan N; Shafat I; Zcharia E; Goldshmidt O; Vlodavsky I
J Thromb Haemost; 2006 Nov; 4(11):2443-51. PubMed ID: 16970801
[TBL] [Abstract][Full Text] [Related]
33. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
34. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis.
Bayam E; Kalçık M; Gürbüz AS; Yesin M; Güner A; Gündüz S; Gürsoy MO; Karakoyun S; Cerşit S; Kılıçgedik A; Candan Ö; Yaman A; Özkan M
Thromb Res; 2018 Nov; 171():103-110. PubMed ID: 30273810
[TBL] [Abstract][Full Text] [Related]
35. Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity.
Wang J; Pendurthi UR; Rao LVM
Blood; 2019 Aug; 134(7):645-655. PubMed ID: 31262782
[TBL] [Abstract][Full Text] [Related]
36. [Significance of Tissue Factor-Bearing Microparticle Procoagulation Activity and Antithrombin Ⅲ Detection in Thalassemia Patients].
Su X; Liu H; Sun N; Cheng P; Deng DH; Long Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):539-544. PubMed ID: 30998167
[TBL] [Abstract][Full Text] [Related]
37. Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo.
Kopec AK; Spada AP; Contreras PC; Mackman N; Luyendyk JP
Toxicol Sci; 2018 Apr; 162(2):396-405. PubMed ID: 29228388
[TBL] [Abstract][Full Text] [Related]
38. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
39. Hypercoagulable state in five thalassemia intermedia patients.
Bhattacharyya M; Kannan M; Chaudhry VP; Mahapatra M; Pati H; Saxena R
Clin Appl Thromb Hemost; 2007 Oct; 13(4):422-7. PubMed ID: 17911195
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles.
Muhsin-Sharafaldine MR; Kennedy BR; Saunderson SC; Buchanan CR; Dunn AC; Faed JM; McLellan AD
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):286-295. PubMed ID: 27864149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
